Validation of candidate genes associated with cardiovascular risk factors in psychiatric patients

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 36, Issue 2, 2012, Pages 213-219

  Windemuth, Andreas ^a   De Leon, Jose ^b   Goethe, John W ^a   Schwartz, Harold I ^a   Woolley, Stephen ^a   Susce, Margaret ^b   Kocherla, Mohan ^a   Bogaard, Kali ^a   Holford, Theodore R ^c   Seip, Richard L ^a   Ruaño, Gualberto ^a  

^a HARTFORD HOSPITAL   (United States)

^b Eastern State Hospital   (United States)

^c YALE UNIVERSITY   (United States)

Author keywords

Antipsychotics; Lipid metabolism; Obesity; Personalized medicine; Pharmacogenetics; Triglycerides

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; TRIACYLGLYCEROL; ZIPRASIDONE;

ABCA1 GENE; ADULT; AGED; ANGPTL3 GENE; APOA5 GENE; APOB GENE; APOE GENE; ARTICLE; B3GALT4 GENE; B4GALT4 GENE; BIPOLAR DISORDER; BODY MASS; CARDIOVASCULAR RISK; CELSR2 GENE; CETP GENE; CHOLESTEROL BLOOD LEVEL; DISEASE SEVERITY; FEMALE; FTO GENE; GALNT2 GENE; GCKR GENE; GENE; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENOTYPE; GRIN3A GENE; HUMAN; KCTD15 GENE; LCAT GENE; LDLR GENE; LIPC GENE; LIPG GENE; LPL GENE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MC4R GENE; MENTAL HOSPITAL; MENTAL PATIENT; MLXIPL GENE; MOOD DISORDER; MTCH2 GENE; MVK GENE; NCAN GENE; NEGR1 GENE; OBESITY; PCSK9 GENE; PHENOTYPE; PSYCHOSIS; RBKS GENE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SH2B1 GENE; SINGLE NUCLEOTIDE POLYMORPHISM; TMEM18 GENE; TRIACYLGLYCEROL BLOOD LEVEL; TRIB1 GENE; UNITED STATES;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; BODY MASS INDEX; CARDIOVASCULAR DISEASES; CHOLESTEROL; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; TRIGLYCERIDES;

EID: 84855341054     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2011.08.001     Document Type: Article

References (52)

1. Adkins D.E., Aberg K., McClay J.L., Bukszar J., Zhao Z., Jia P., et al. Genome wide pharmacogenomic study of metabolic side effects to antipsychotic drugs. Mol Psychiatry 2010, 16:321-332.
2. Anon Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143-3421.
3. Athanasiu L., Mattingsdal M., Kahler A.K., Brown A., Gustafsson O., Agartz I., et al. Gene variants associated with schizophrenia in a Norwegian genome-wide study are replicated in a large European cohort. J Psychiatr Res 2010, 44:748-753.
4. Barbui C. Antidepressants and the risk of suicidal behaviors. JAMA 2004, 292:2833.
5. Blanc O., Brousse G., Meary A., Leboyer M., Llorca P.M. Pharmacogenetic of response efficacy to antipsychotics in schizophrenia: pharmacodynamic aspects. Review and implications for clinical research. Fundam Clin Pharmacol 2010, 24:139-160.
6. Blank K., Szarek B.L., Goethe J.W. Metabolic abnormalities in adult and geriatric major depression with and without comorbid dementia. J Clin Hypertens (Greenwich) 2010, 12:456-461.
7. Centers for Disease Control and Prevention (CDC): National Center for Health statistics (NCHS) (2008) National health and examination survey. U.S. Department of Health and Human Services.
8. Correll C.U., Frederickson A.M., Kane J.M., Manu P. Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs. J Clin Psychiatry 2006, 67:575-583.
9. Correll C.U., Manu P., Olshanskiy V., Napolitano B., Kane J.M., Malhotra A.K. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 2009, 302:1765-1773.
10. de Leon J., Diaz F.J. Planning for the optimal design of studies to personalize antipsychotic prescriptions in the post-CATIE era: the clinical and pharmacoepidemiological data suggest that pursuing the pharmacogenetics of metabolic syndrome complications (hypertension, diabetes mellitus and hyperlipidemia) may be a reasonable strategy. Schizophr Res 2007, 96:185-197.
11. de Leon J., Susce M.T., Pan R.M., Fairchild M., Koch W.H., Wedlund P.J. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry 2005, 66:15-27.
12. de Leon J., Susce M.T., Johnson M., Hardin M., Pointer L., Ruano G., et al. A clinical study of the association of antipsychotics with hyperlipidemia. Schizophr Res 2007, 92:95-102.
13. de Leon J., Correa J.C., Ruano G., Windemuth A., Arranz M.J., Diaz F.J. Exploring genetic variations that may be associated with the direct effects of some antipsychotics on lipid levels. Schizophr Res 2008, 98:40-46.
14. Diaz F.J., Meary A., Arranz M.J., Ruano G., Windemuth A., de Leon J. Acetyl-coenzyme A carboxylase alpha gene variations may be associated with the direct effects of some antipsychotics on triglyceride levels. Schizophr Res 2009, 115:136-140.
15. Foster A., Miller d.D., Buckley P. Pharmacogenetics and schizophrenia. Clin Lab Med 2010, 30:975-993.
16. Franciosi L.P., Kasper S. Advancing the treatment of people with mental illness: a call to action in the management of metabolic issues. J Clin Psychiatry 2005, 66:790-798.
17. Frayling T.M., Timpson N.J., Weedon M.N., Zeggini E., Freathy R.M., Lindgren C.M., et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science 2007, 316:889-894.
18. Goethe J.W., Szarek B.L., Caley C.F., Woolley S.B. Signs and symptoms associated with the metabolic syndrome in psychiatric inpatients receiving antipsychotics: a retrospective chart review. J Clin Psychiatry 2007, 68:22-28.
19. Goethe, J. W., Szarek, B. L., Blank, K., and Caley, C. F. (2009a) Metabolic Syndrome in patients with major depressive disorder: Associated risk factors. Psychiatric Times.
20. Goethe J.W., Szarek B.L., Caley C.F. Metabolic syndrome in psychiatric inpatients treated for depression. Metabolic Effects of Psychotropic Drugs 2009, 90-104. Karger, Basel. J. Thakore, B. Leonard (Eds.).
21. Gurwitz D., McLeod H.L. Primum non nocere: adverse drug events must be taken seriously. Pharmacogenomics 2007, 8:311-314.
22. Harwood H.J. Treating the metabolic syndrome: acetyl-CoA carboxylase inhibition. Expert Opin Ther Targets 2005, 9:267-281.
23. Kahn R., Buse J., Ferrannini E., Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005, 28:2289-2304.
24. Kohen I., Manu P. Rapidly worsening hypertriglyceridemia during treatment with risperidone. Am J Ther 2010, 17:216-218.
25. Lamberti J.S., Olson D., Crilly J.F., Olivares T., Williams G.C., Tu X., et al. Prevalence of the metabolic syndrome among patients receiving clozapine. Am J Psychiatry 2006, 163:1273-1276.
26. Li X., Song F., Jiang H., Zhang M., Lin J., Bao W., et al. A genetic variation in the fat mass- and obesity-associated gene is associated with obesity and newly diagnosed type 2 diabetes in a Chinese population. Diabetes Metab Res Rev 2010, 26:128-132.
27. Loos R.J., Lindgren C.M., Li S., Wheeler E., Zhao J.H., Prokopenko I., et al. Common variants near MC4R are associated with fat mass, weight and risk of obesity. Nat Genet 2008, 40:768-775.
28. Lusis A.J., Pajukanta P. A treasure trove for lipoprotein biology. Nat Genet 2008, 40:129-130.
29. Mackin P., Bishop D., Watkinson H., Gallagher P., Ferrier I.N. Metabolic disease and cardiovascular risk in people treated with antipsychotics in the community. Br J Psychiatry 2007, 191:23-29.
30. McEvoy J.P., Meyer J.M., Goff D.C., Nasrallah H.A., Davis S.M., Sullivan L., et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005, 80:19-32.
31. Meyer J.M. Novel antipsychotics and severe hyperlipidemia. J Clin Psychopharmacol 2001, 21:369-374.
32. Meyer J., Loh C., Leckband S.G., Boyd J.A., Wirshing W.C., Pierre J.M., et al. Prevalence of the metabolic syndrome in veterans with schizophrenia. J Psychiatr Pract 2006, 12:5-10.
33. Mick E., McGough J.J., Middleton F.A., Neale B., Faraone S.V. Genome-wide association study of blood pressure response to methylphenidate treatment of attention-deficit/hyperactivity disorder. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35:466-472.
34. Newcomer J.W. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005, 19(Suppl 1):1-93.
35. Newton-Cheh C., Johnson T., Gateva V., Tobin M.D., Bochud M., Coin L., et al. Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet 2009, 41:666-676.
36. NIMHS (2009) National Institute of Mental Health Statistics. U.S. Department of Health and Human Services.
37. Olfson M., Marcus S.C., Corey-Lisle P., Tuomari A.V., Hines P., L'Italien G.J. Hyperlipidemia following treatment with antipsychotic medications. Am J Psychiatry 2006, 163:1821-1825.
38. Panz V.R., Raal F.J., Paiker J., Immelman R., Miles H. Performance of the CardioChek PA and Cholestech LDX point-of-care analysers compared to clinical diagnostic laboratory methods for the measurement of lipids. Cardiovasc J S Afr 2005, 16:112-117.
39. Paterson A.D., Waggott D., Boright A.P., Hosseini S.M., Shen E., Sylvestre M.P., et al. A genome-wide association study identifies a novel major locus for glycemic control in type 1 diabetes, as measured by both A1C and glucose. Diabetes 2010, 59:539-549.
40. Ruaño G., Goethe J.W., Caley C., Woolley S., Holford T.R., Kocherla M., et al. Physiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients. Mol Psychiatry 2007, 12:474-482.
41. Scott L.J., Mohlke K.L., Bonnycastle L.L., Willer C.J., Li Y., Duren W.L., et al. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 2007, 316:1341-1345.
42. Sernyak M.J., Leslie D.L., Alarcon R.D., Losonczy M.F., Rosenheck R. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002, 159:561-566.
43. Sladek R., Rocheleau G., Rung J., Dina C., Shen L., Serre D., et al. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 2007, 445:881-885.
44. Snyder E.M., Murphy M.R. Schizophrenia therapy: beyond atypical antipsychotics. Nat Rev Drug Discov 2008, 7:471-472.
45. Sparso T., Bonnefond A., Andersson E., Bouatia-Naji N., Holmkvist J., Wegner L., et al. G-allele of intronic rs10830963 in MTNR1B confers increased risk of impaired fasting glycemia and type 2 diabetes through an impaired glucose-stimulated insulin release: studies involving 19,605 Europeans. Diabetes 2009, 58:1450-1456.
46. Susce M.T., Villanueva N., Diaz F.J., de Leon J. Obesity and associated complications in patients with severe mental illnesses: a cross-sectional survey. J Clin Psychiatry 2005, 66:167-173.
47. Szarek B.L., Goethe J.W., Woolley S.B. Assessing metabolic syndrome: waist circumference versus BMI. Schizophr Res 2009, 108:295-296.
48. Uher R., Perroud N., Ng M.Y., Hauser J., Henigsberg N., Maier W., et al. Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. Am J Psychiatry 2010, 167:555-564.
49. Wampers M, Hanssens L, van WR, Heald A, Collette J, Peuskens J, et al. Differential effects of olanzapine and risperidone on plasma adiponectin levels over time: results from a 3-month prospective open-label study. Eur Neuropsychopharmacol in press.
50. Willer C.J., Sanna S., Jackson A.U., Scuteri A., Bonnycastle L.L., Clarke R., et al. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet 2008, 40:161-169.
51. Willer C.J., Speliotes E.K., Loos R.J., Li S., Lindgren C.M., Heid I.M., et al. Six new loci associated with body mass index highlight a neuronal influence on body weight regulation. Nat Genet 2009, 41:25-34.
52. Zeggini E., Weedon M.N., Lindgren C.M., Frayling T.M., Elliott K.S., Lango H., et al. Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science 2007, 316:1336-1341.